Navigation Links
338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
Date:9/4/2008

SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced that the pivotal clinical study of Polidocanol, conducted in Germany by BioForm Medical's partner, Chemische Fabrik KREUSSLER & Co. GmbH (Kreussler), successfully met the study primary endpoint and has been submitted to FDA as part of a New Drug Application (NDA) process.

In the pivotal clinical study, named the EASI (Efficacy and safety of Aethoxysklerol compared to Sodium Tetradecyl Sulfate and Isotonic Saline) study, 338 patients with C1 varicose veins (either spider veins of <1mm diameter or reticular veins of 1-3mm diameter), were randomized to receive either Polidocanol (also called Lauromacrogol 400, European tradename, Aethoxysklerol(R)), Sodium-tetradecyl-sulfate (STS or Sotradecol(R), an effective control), or Isotonic saline (a placebo control). Patients were followed for 26 weeks (6 months) with standardized photography of a defined 10x10 cm area of the leg at baseline, 12 weeks and 26 weeks. These photographs were rated by the treating physicians and two blinded evaluators, which served as the basis for efficacy assessment.

The EASI study successfully met its primary efficacy endpoint with demonstrated statistically significant superiority (p<0.0001) of Polidocanol versus placebo. The treatment success rates for Polidocanol were 96% and 95% at 12 and 26 weeks, compared to STS (92%, 91%) and placebo (8%, 6%). A secondary endpoint analysis demonstrated that significantly more patients were satisfied or very satisfied with Polidocanol at 12 or 26 weeks (88%, 84%), compared to STS (63%, 64%; p<0.0001) or placebo (13%, 11%; p<0.0001). Polidocanol was found to be safe and well tolerated in the study. The incidence
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Agendia Launches TargetPrint(R) for Breast Cancer Patients
4. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
5. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
6. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
7. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
10. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
11. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Physician E-sampling is becoming well established across ... key marketing sales tactic in recent years. However, some ... a supplement to traditional sampling. According ... E-sampling has been seeded across multiple therapeutic areas- including ... has been in place for five or more years ...
(Date:9/4/2015)... 2015  Janssen Research & Development, LLC (Janssen) ... (FDA) has accepted for Priority Review the Biologics ... for patients with multiple myeloma who are refractory ... immunomodulatory agent (IMiD), or who have received three ... PI and an IMiD. This is referred to ...
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
... Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at ... ... (Nasdaq: ANDS ) announced today preliminary results of a Phase I,clinical trial ... trial of ANA598 in patients chronically infected,with hepatitis C virus (HCV). In the ...
... Rehovot, Israel, reported today results of its internal,clinical trial of ... cancer., In the trial a total of 76 sputum ... Healthy individuals that never smoked 2. Heavy smokers with ... cancer patients (Stage 1) 4. Advanced stage lung cancer ...
Cached Medicine Technology:Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 2Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 3Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 4Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 5Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 6BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test 2
(Date:9/4/2015)... ... 04, 2015 , ... The Schmidt National Law Group filed an Essure® lawsuit ... Schmidt National Law Group, a leading firm in mass-tort litigation, has filed a lawsuit ... Essure, Inc., and other Bayer affiliates for injuries alleged to have been caused by ...
(Date:9/4/2015)... ... 04, 2015 , ... IVF New England, one of the largest and most ... Hour" in Manchester for women who wish to learn more about their fertility and ... and lounge, 827 Elm Street, Manchester, NH from 6PM to 7PM , This hip, ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms ... of new apparel. In an effort to assist the team, the Jones Agency, a ... charity drive to raise funds for the new uniforms. , As is so often ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... to benefit Core Compassion Project. Core Compassion Project is a non-profit organization ... to reduce the side effects of cancer treatments and recover their mobility, strength, ...
(Date:9/4/2015)... ... 04, 2015 , ... Keeping mold top of mind is important when considering ... Mold can grow anywhere - on carpet, clothing, food, paper, and even in places ... water in the home is key to preventing mold growth, which if exposed to ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4
... by researchers from Ireland, Boston and the Netherlands, it ... rates Cleaning up the air really can save lives. The ... 1990 ban on coal in Dublin. They studied the death ... was implemented. After the ban, the amount of black smoke ...
... at least once a week have a reduced risk of dementia. ... people aged over 65 //and without dementia at the beginning. They ... then followed them up to, five and seven years afterwards. ... week had a significantly lower risk of being diagnosed with dementia ...
... the effect of Chinese herbal extracts along with cancer ... as a way of increasing the side effects ... Hong Kong are now subjecting the extracts to a ... recruited 75 patients with either breast or colon cancer. ...
... According to a new study it is observed that motivating ... not necessarily more effective than just ordering them to quit. ... more responsive than ever before to the idea of giving ... in Melbourne, have been considering at the best way to ...
... slow the advancement of the disease. Researchers report immediate treatment ... the progression of vision loss.// This has very few significant ... detailed eye exam. In this study, doctors recruited 202 patients ... of the group was treated with medicine and laser to ...
... promises a better result for people with Hodgkin's disease. ... of those who develop// Hodgkin's disease. But their recovery ... conventional radiation treatment. , ,The problem lies with ... way. But researchers at Stanford University have been developing ...
Cached Medicine News:
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
Medicine Products: